Tong Ren Tang to acquire CLSA Premium for HKD250m.

Synopsis

Tong Ren Tang, a Chinese pharmaceutical company, agreed to acquire CLSA Premium, an investment holding company selling healthcare products and other services, for HKD250m.

Principals

target

Clsa Premium

bidder

Beijing Tong Ren Tang

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (4)

yuan feng

Executive Director at CLSA PREMIUM LIMITED

Manager

target

Deal

£ 26 M

Total Value

roger cheng

Partner at Linklaters

Lawyer

target

Deals

£ 21.83 B

Total Value

tiffany yan

Counsel at Linklaters

Lawyer

target

Deals

£ 3.14 B

Total Value

alison chan

‎Associate at Linklaters

Lawyer

target

Deals

£ 179 M

Total Value

Bidder Team (1)

ji guangfei

Director at BEIJING TONG REN TANG

Manager

bidder

Deal

£ 26 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy